Etrasimod Dose-Ranging Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of Etrasimod in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071210052

Enrollment

Registered

2021-08-19

Start date

2021-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Eligible subjects will be randomized (1:1:1ratio) to receive either etrasimod (dose A), etrasimod (dose B), or matching placebo (once daily) in a double-blind fashion for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Japanese ancestry - Diagnosed with ulcerative colitis (UC) => 3 months prior to screening - Having active UC confirmed by endoscopy - Moderately to severely active UC

Exclusion criteria

Exclusion criteria: - Severe extensive colitis - Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence, history of a fistula consistent with CD - Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

Design outcomes

Primary

Measure	Time frame
The proportion of subjects achieving clinical remission at Week 12	—

Contacts

Public ContactjRCT Call Center IQVIA Services Japan K.K.

IQVIA Services Japan K.K.

JP_Arena_ELEVATE_UC@iqvia.com+81-120-229-053

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026